Showing results (1-10 of 5) with videos related to
Sort By:
Pageof 1
The Oncologist|December 16, 2010
The European Medicines Agency review of ofatumumab (Arzerra®) for the treatment of chronic lymphocytic leukemia in patients refractory to fludarabine and alemtuzumab: summary of the scientific assessment of the European medicines agency committee for medicinal products for human useIordanis Gravanis, Jens Ersbøll, Eva Skovlund, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 26, 2012
The European medicines agency review of eribulin for the treatment of patients with locally advanced or metastatic breast cancer: summary of the scientific assessment of the committee for medicinal products for human useElias Pean, Sigrid Klaar, Eva Gil Berglund, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2011
The European Medicines Agency review of pazopanib for the treatment of advanced renal cell carcinoma: summary of the scientific assessment of the Committee for Medicinal Products for Human UseMaria Nieto, Jeanett Borregaard, Jens Ersbøll, et al.The Oncologist|June 15, 2014
The European Medicines Agency Review of Pertuzumab for the treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer: summary of the scientific assessment of the committee for medicinal products for human useHector Boix-Perales, Jeanett Borregaard, Kristina Bech Jensen, et al.The Oncologist|January 25, 2015
The European Medicines Agency approval of axitinib (Inlyta) for the treatment of advanced renal cell carcinoma after failure of prior treatment with sunitinib or a cytokine: summary of the scientific assessment of the committee for medicinal products for human useKyriaki Tzogani, Venke Skibeli, Ingunn Westgaard, et al.Pageof 1